KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Vertex Pharmaceuticals (VRTX) Revenue (2016 - 2025)

Historic Revenue for Vertex Pharmaceuticals (VRTX) over the last 17 years, with Q3 2025 value amounting to $3.1 billion.

  • Vertex Pharmaceuticals' Revenue rose 1098.52% to $3.1 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $11.7 billion, marking a year-over-year increase of 1032.86%. This contributed to the annual value of $11.0 billion for FY2024, which is 1166.15% up from last year.
  • Vertex Pharmaceuticals' Revenue amounted to $3.1 billion in Q3 2025, which was up 1098.52% from $3.0 billion recorded in Q2 2025.
  • Vertex Pharmaceuticals' Revenue's 5-year high stood at $3.1 billion during Q3 2025, with a 5-year trough of $1.7 billion in Q1 2021.
  • In the last 5 years, Vertex Pharmaceuticals' Revenue had a median value of $2.5 billion in 2023 and averaged $2.4 billion.
  • Per our database at Business Quant, Vertex Pharmaceuticals' Revenue skyrocketed by 2898.25% in 2021 and then skyrocketed by 295.84% in 2025.
  • Over the past 5 years, Vertex Pharmaceuticals' Revenue (Quarter) stood at $2.1 billion in 2021, then rose by 11.1% to $2.3 billion in 2022, then grew by 9.34% to $2.5 billion in 2023, then increased by 15.66% to $2.9 billion in 2024, then grew by 5.65% to $3.1 billion in 2025.
  • Its Revenue was $3.1 billion in Q3 2025, compared to $3.0 billion in Q2 2025 and $2.8 billion in Q1 2025.